Clopidogrel and the reduced-function CYP2C19 genetic variant: a limited piece of the overall therapeutic puzzle.

摘要

EFFECTIVE PLATELET INHIBITION HAS BECOME A COR-nerstone in the management of patients with acute coronary syndrome (ACS). The addition of clopi-dogrel to aspirin has provided significant reductions in major cardiovascular events in patients with ACS in general, and particularly among those treated invasively by percutaneous coronary intervention (PCI).1 Yet studies have demonstrated that the therapeutic response of clopi-dogrel is variable among patients,2 and low or incomplete platelet inhibition has been associated with increased risk for major adverse cardiovascular events.